Evidence map›Paper›PMID 32564788›Full record

ReviewAdvances in clinical chemistry2020

Pleiotrophin: Activity and mechanism.

Xu Wang

Abstract readReview
In one paragraph

Review in Advances in clinical chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Diminished pleiotrophin as a new clue to pre-eclampsia: Linking impaired angiogenesis to adverse outcomes.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Post-Critical Period Transcriptional and Physiological Adaptations of Primary Sensory Cortex after Sensory Loss.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2026
    Article
  12. World journal of gastroenterology · 2026
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Xu WangSchool of Molecular Sciences, Arizona State University, Tempe, AZ, United States. Electronic address: xuwang@asu.edu.

Funding

Interactions of pleiotrophin with receptor type protein tyrosine phosphataseR01GM118518 · NIGMS · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI WANG, XU · 2017 to 2021
$1.6M
NIGMS NIH HHS R01 GM118518
6 · The paper itself

Abstract

Pleiotrophin (PTN) is a potent mitogenic cytokine with a high affinity for the polysaccharide glycosaminoglycan (GAG). Although it is most strongly associated with neural development during embryogenesis and the neonatal period, its expression has also been linked to a plethora of other physiological events including cancer metastasis, angiogenesis, bone development, and inflammation. A considerable amount of research has been carried out to understand the mechanisms by which PTN regulates these events. In particular, PTN has now been shown to bind a diverse collection of receptors including many GAG-containing proteoglycans. These interactions lead to the activation of many intracellular kinases and, ultimately, activation and transformation of cells. Structural studies of PTN in complex with both GAG and domains from its non-proteoglycan receptors reveal a binding mechanism that relies on electrostatic interactions and points to PTN-induced receptor oligomerization as one of the possible ways PTN uses to control cellular functions.

Indexed as

AnimalsCarrier ProteinsCell DifferentiationCytokinesHumansNeoplasmsCarrier ProteinsCytokinespleiotrophinAngiogenesisGlycosaminoglycanNeural regenerationPleiotrophinPTPRZ

Identifiers

PMID32564788
PMCPMC7672882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.